Using neem tree extracts as a starting point, scientists have created several kinds of nanozymes and tested them for ...

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

A scientist says he has shown that it’s possible to produce a large amount of virus-like particles using a fully scalable process.

Single-use continuous bioprocessing can reduce mAb production costs and shorten time-to-market compared to batch processing.